Disposition of 6708 shares by Schuth Alexander O. of Denali Therapeutics at 5.28 subject to Rule 16b-3
DNLI Stock | USD 21.26 0.42 2.02% |
Under 67 percent of all Denali Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Denali Therapeutics suggests that a large number of traders are confidant. Denali Therapeutics' investing sentiment shows overall attitude of investors towards Denali Therapeutics.
Denali |
Filed transaction by Denali Therapeutics Officer: Cofo And Secretary. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Denali Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Denali Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Denali Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Denali Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Denali Therapeutics Maximum Pain Price Across January 17th 2025 Option Contracts
Denali Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Denali Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Denali Therapeutics' options.
Denali Therapeutics Fundamental Analysis
We analyze Denali Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Denali Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Denali Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Denali Therapeutics stock to make a market-neutral strategy. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics with similar companies.
Peers
Denali Therapeutics Related Equities
TVTX | Travere Therapeutics | 8.90 | ||||
DSGN | Design Therapeutics | 7.94 | ||||
HOWL | Werewolf Therapeutics | 7.69 | ||||
RNA | Avidity Biosciences | 7.22 | ||||
SWTX | SpringWorks Therapeutics | 5.85 | ||||
LEGN | Legend Biotech | 3.02 | ||||
BDTX | Black Diamond | 2.80 | ||||
IKNA | Ikena Oncology | 2.42 | ||||
STOK | Stoke Therapeutics | 1.95 | ||||
PCVX | Vaxcyte | 1.76 | ||||
ASND | Ascendis Pharma | 1.74 | ||||
FDMT | 4D Molecular | 1.72 | ||||
BPMC | Blueprint Medicines | 1.32 | ||||
APLS | Apellis Pharmaceuticals | 0.90 | ||||
GLUE | Monte Rosa | 0.84 | ||||
AKRO | Akero Therapeutics | 0.57 | ||||
BGNE | BeiGene | 0.49 | ||||
RVMD | Revolution Medicines | 0.27 | ||||
DAWN | Day One | 0.94 |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Directory Find actively traded commodities issued by global exchanges |